Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5858/arpa.2023-0117-LE | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of inflammation and steroids on anti-coagulation in children supported on a ventricular assist device.
J Artif Organs
December 2024
Cincinnati Children's Hospital Medical Center, Main Street, Cincinnati, OH, 77030, USA.
Critically ill pediatric patients supported on ventricular assist devices (VADs) are increasingly being anticoagulated on bivalirudin, but with difficulty monitoring anticoagulation. Activated partial thromboplastin time (aPTT) has recently been shown to poorly correlate with bivalirudin plasma concentrations, while dTT had excellent correlation. However, aPTT is the more common monitoring test and dTT testing is rarely used.
View Article and Find Full Text PDFBivalirudin Stability in Citrated Plasma and Citrated Whole Blood.
Arch Pathol Lab Med
January 2024
Department of Pathology, Texas Children's Hospital, Houston.
Anticoagulation Stability With Bivalirudin: Positioning the Horse Before the Cart.
ASAIO J
November 2023
Department of Pediatrics, Columbia University Irving Medical Center, New York, New York.
Bivalirudin Compared to Heparin as the Primary Anticoagulant in Pediatric Berlin Heart Recipients.
ASAIO J
May 2023
From the Department of Pharmacy, NewYork-Presbyterian Hospital.
Bivalirudin has been used in increasing frequency as an alternative to unfractionated heparin (UFH) in pediatric recipients of Berlin Heart EXCOR ventricular assist devices (VAD). This single-center, retrospective review characterizes anticoagulant trends and outcomes in pediatric Berlin Heart VAD recipients implanted between September 1, 2013, and August 31, 2021, anticoagulated with either bivalirudin or UFH. Thirty-one patients were included; 65% who received bivalirudin and 35% who received UFH.
View Article and Find Full Text PDFIs bivalirudin an alternative anticoagulant for extracorporeal membrane oxygenation (ECMO) patients? A systematic review and meta-analysis.
Thromb Res
February 2022
Department of Institute for Emergency and Disaster Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China; Sichuan Provincial Research Center for Emergency Medicine and Critical Illness, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China. Electronic address:
Background: Anticoagulation is important for extracorporeal membrane oxygenation (ECMO). Heparin is widely used; however, in some cases, it is not suitable for patients. Bivalirudin has been recently proposed for ECMO patients, and there is no evidence regarding its effectiveness and safety.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!